SlideShare a Scribd company logo
Merck KGaA
Darmstadt, Germany
Lisa L. McDermott
Director, Process and Analytical Development
Olaf Bartram
Global Product Manager, PEGs and Innovative Technologies
Benefits of
monodisperse &
Activated PEGs to
Accelerate ADC
Development
The life science business of
Merck KGaA, Darmstadt, Germany
operates as MilliporeSigma
in the U.S. and Canada.
Monodisperse PEGs in ADCs
Presentation Overview
2
Executive Summary
3
1
4
Hydrophobicity Challenges
Summary
Critical PEG Attributes
• Aggregation of Final ADC
• Drug Load Limitations
• High loaded species need to be removed
• Limit R&D to low DAR Analogues
• PK/PD impact
• Fast clearance rate
• Rate increased with increasing DAR
• increased lipophilicity
• Decreased therapeutic window
Monodisperse PEGs in ADCs
Challenges Encountered with Hydrophobic Toxins
Impact of toxin solubility
• Alternative scaffolds
• Optimize linker to offset lipophilicity of payload
• Site specific payload attachment
• Payload bearing site modification
• SAR mAb, payload, linker and conjugation method
• Alternative Formulation or Additives
Monodisperse PEGs in ADCs
Challenges Encountered with Hydrophobic Toxins
Tools
Monodisperse PEGs in ADCs
Impact of Drug Loading on Efficacy
Higher DARs - Accelerates ADC clearance
Higher DARs - Non-linear impact on tumor growth
Kevin J. Hamblett et al. Clin Cancer Res
2004;10:7063-7070
Pharmacokinetics of cAC10 and cAC10–
antibody-drug conjugates. SCID mice were
injected via the tail vein with 10 mg/kg
cAC10, E2, E4, and E8. Plasma samples were
analyzed by ELISA to determine the antibody
or antibody-drug conjugate concentration.
DAR2
DAR8
DAR4
DAR0
Why PEGs can help?
• Improved pharmacokinetics
• Enhanced solubility
• Improved stability
• Increased circulation time
• Decreased amount of protein required for therapeutic
efficacy
• Decreased dosing frequency due to optimized
biodistribution
• Reduced renal clearance increases circulation time
• Decreased toxicity
• Improved safety profile
• Reduced immunogenicity
• Reduced antigenicity
• Reduced proteolysis
• Generally recognized as safe (GRAS status by FDA)
Dumb-Bell like PEG-drug structure
Monodisperse PEGs in ADCs
Monodisperse PEGs in ADCs
Transfer of the protein pegylation concept to ADCs with DAR8:
what is the desired PEG size?
Maleimide-PEG-Glucuronide-MMAE with variable PEG lengths
Burke et al., Mol Cancer Ther 16(1) 116
Monodisperse PEGs in ADCs
Pharmacokinetic and clearance is a function of PEG length, demonstrated
for a DAR8 ADC
Burke et al., Mol Cancer Ther 16(1) 116
Monodisperse PEGs in ADCs
Increasing PEG length shows a positive effect on Pharmacodynamic and
increased tolerability and mouse survival rate
Burke et al., Mol Cancer Ther 16(1) 116
Monodisperse PEGs in ADCs
Selected Microtubule Targeting Drug Linkers that contain PEG Groups
DBCO-PEG4-linker MMAF payload
(http://www.globalengage.co.uk/biologics/docs/Steiner.pdf , Sutro)
PEG4, Mar. Drugs 2017, 15, 99
https://pdfs.semanticscholar.org/40fe/c075fbef09881fd87402276267645af078a7.pdf
Mol Cancer Ther; 16(1) January 2017, 116-123
SGN-CD48a, PEG12, SeattleGenetics
Monodisperse PEGs in ADCs
Selected DNA Targeting Drug Linkers that Contain PEG Groups
Nature Reviews, 2017 (16) 315
PEG3, Immunogen
ACS Med Chem Lett 2016, 7, 983 PEG8, Spirogen
Mol Cancer Ther 2018, 17(10), 2176 , Immunogen
Oncotarget Vol.6, No.26,
22496
PEG8, Immunomedics
Monodisperse PEGs in ADCs
Linear and branched PEG in ADC examples
CD-70, PEG2+2*4 ,
Ambrex
US20150141624A1
HU2H11, PEG5, Sanofi
Molecules 2017, 22(8),
1281
Monodisperse PEGs in ADCs
Presentation Overview
2
Executive Summary
3
1
4
Hydrophobicity Challenges
Summary
Critical PEG Attributes
1. PEGs are well known substances, generally recognized as safe (GRAS), biologically inert
with hydrophilic properties
2. Widely used as non-toxic auxiliary materials in multiple technical applications and
amongst others in cosmetics and food and pharmaceuticals (such as medical treatment of
constipation)
3. After synthetic activation PEGs can be conjugated (PEGylated) with proteins, peptides,
small molecules or can act as linkers in ADCs.
4. PEGylated products show improved pharmacokinetics, increased circulation time and
decreased toxicity.
Introduction Polyethylene Glycol (PEG)
Monodisperse PEGs in ADCs
16
Monodisperse PEGs in ADCs
Polydisperse PEGs
• Statistical distribution results from equal probabilities of ethylene oxide polymerizations.
There is only a neglectable difference between PEG fractions of different chain lengths.
• Thus even under the most ideal conditions a distribution will be obtained. If the conditions
are not ideal, the distribution will deteriorate even more.
Polymerizations will result always in a molecular weight distribution.
17
Monodisperse PEGs in ADCs
Monodisperse PEGs
• Monodisperse PEGs do have an impact on the pharmacokinetic and
pharmacodynamics of your ADC
• Production of monodisperse PEGs by purification of polydisperse PEGs
or synthesis of defined PEG units with the same molecular weight
• Typically used for ADCs are PEG4 – PEG24 units
• Maleimide as functional group is targeting cysteine at the antibody
• Functional azide group connects to payload
• High purity and defined impurity profile are beneficial for registration
• High GMP level required for successful commercialisation of your ADC
ADCs require monodisperse PEGs as linkers with a uniform molecular mass.
18
Monodisperse PEGs in ADCs
Monodisperse PEGs
• Target purity of 90-95% or higher - depends on analytical method
• Sensitive to oxidation and hydrolysis - determined via derivatization
• Adsorption of elemental impurities (heavy metals), salts, polar
compounds
 Control elemental impurities via ICP-MS
 Control residual solvents and reagents via GC, IC, KF and HPLC
Purity of monodisperse PEGs is the main quality parameter.
Separation of single PEG units in relation to PEG size
Figure: Separation of different PEGs using HPLC-CAD. Sample concentration for all: 0.1 mg/mL.
Source: C. Theiss, U. Holzgrabe / Journal of Pharmaceutical and Biomedical Analysis 160 (2018) 212–221
Monodisperse PEGs in ADCs
Lower number of PEG units are easier to separate.
Approx. 7-23
PEG units
Comparison of detector responses
CAD
ELSD
UV
Mass on detector
Relativedetectorresponse
 Both ELSD and CAD have non-linear
response curves compared to UV.
 ELSD tends to underestimate low level
signals.
 LoQ is typically lower for CAD compared
to ELSD.
 CAD overestimates small impurities.
 For both - CAD and ELSD - small, semi-
volatile compounds might be evaporated
and therefore not visible or
underestimated.
 Understanding the characteristics of the
different detectors is key for the correct
interpretation of analytical results.
CAD = Charged Aerosol Detector
ELSD = Evaporative Light Scattering Detector
UV = UV Detector
Monodisperse PEGs in ADCs
CAD-ELSD-UV
Widely used UV detectors are not applicable for PEGs as such.
ELSD
 Purity: 98.9 % area
 Largest impurity: 1.0 % area
 Number of impurities: 5
Monodisperse PEGs in ADCs
Case study: Same sample measured with Evaporative Light
Scattering Detector (ELSD) and Charged Aerosol Detector (CAD)
ELSD
 Purity: 98.9 % area
 Largest impurity: 1.0 % area
 Number of impurities: 5
Monodisperse PEGs in ADCs
Case study: Same sample measured with Evaporative Light
Scattering Detector (ELSD) and Charged Aerosol Detector (CAD)
CAD
 Purity: 89.0 % area
 Largest impurity: 5.8 % area
 Number of impurities: 18
Interpretation of CAD and ELSD derived results need solid analytical knowledge
Penta ethylene glycol (PEG 5) Hexa ethylene glycol (PEG 6)
Monodisperse PEGs in ADCs
Gas Chromatography (GC) for volatile compounds
PEGs up to approx. six ethylene glycol units are volatile enough to be analyzed by GC.
Monodisperse PEGs in ADCs
Presentation Overview
2
Executive Summary
3
1
4
Hydrophobicity Challenges
Summary
Critical PEG Attributes
• Low solubility of lipophilic payloads limits
high DAR ADCs
• PEGs in ADC linker enables higher soluble
ADCs with higher DARs
• Quality, especially purity of PEGs in ADC is
a key parameter for regulatory success
• Determination of PEG purity depends
significantly on analytical setup
Monodisperse PEGs in ADCs
Summary
Overcoming ADC Solubility Issues
Merck and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners.
Detailed information on trademarks is available via publicly accessible resources.
© 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

More Related Content

What's hot

Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesMerck Life Sciences
 
Webinar: A Scale-up to 2000L, Blindfolded!
Webinar: A Scale-up to 2000L, Blindfolded!Webinar: A Scale-up to 2000L, Blindfolded!
Webinar: A Scale-up to 2000L, Blindfolded!Merck Life Sciences
 
The Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCThe Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCMilliporeSigma
 
Get Proactive With Your Stability Program
Get Proactive With Your Stability ProgramGet Proactive With Your Stability Program
Get Proactive With Your Stability ProgramMerck Life Sciences
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...MilliporeSigma
 
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...MilliporeSigma
 
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...Challenges using Multiple Single-use Systems: Functionality versus Extractabl...
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...Merck Life Sciences
 
Fast-track solutions to address challenges with Host Cell Proteins in early d...
Fast-track solutions to address challenges with Host Cell Proteins in early d...Fast-track solutions to address challenges with Host Cell Proteins in early d...
Fast-track solutions to address challenges with Host Cell Proteins in early d...Merck Life Sciences
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Merck Life Sciences
 
Payload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical TimelinesPayload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical TimelinesMerck Life Sciences
 
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadSmart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadMerck Life Sciences
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationMilliporeSigma
 
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisSee the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisMilliporeSigma
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up MilliporeSigma
 
How to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFFHow to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFFMerck Life Sciences
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesMerck Life Sciences
 
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...Merck Life Sciences
 

What's hot (17)

Accelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell LinesAccelerate Delivery of High Producing Cell Lines
Accelerate Delivery of High Producing Cell Lines
 
Webinar: A Scale-up to 2000L, Blindfolded!
Webinar: A Scale-up to 2000L, Blindfolded!Webinar: A Scale-up to 2000L, Blindfolded!
Webinar: A Scale-up to 2000L, Blindfolded!
 
The Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCThe Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADC
 
Get Proactive With Your Stability Program
Get Proactive With Your Stability ProgramGet Proactive With Your Stability Program
Get Proactive With Your Stability Program
 
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
Solubility Enhancement, Stability and Scalability of Mesoporous Silica Formul...
 
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
Successful Drug Development with Synthetic Lipids: Critical Aspects and Strat...
 
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...Challenges using Multiple Single-use Systems: Functionality versus Extractabl...
Challenges using Multiple Single-use Systems: Functionality versus Extractabl...
 
Fast-track solutions to address challenges with Host Cell Proteins in early d...
Fast-track solutions to address challenges with Host Cell Proteins in early d...Fast-track solutions to address challenges with Host Cell Proteins in early d...
Fast-track solutions to address challenges with Host Cell Proteins in early d...
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
 
Payload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical TimelinesPayload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical Timelines
 
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPadSmart Data Management and Advanced Analytics with Bio4C™ ProcessPad
Smart Data Management and Advanced Analytics with Bio4C™ ProcessPad
 
Webinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 ApplicationWebinar: Novel Perfusion Filter and Controller for N-1 Application
Webinar: Novel Perfusion Filter and Controller for N-1 Application
 
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid AnalysisSee the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
See the Whole Picture: Using SV-AUC for Empty/Full AAV Capsid Analysis
 
Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up	Complete single-use ADC technology from development through scale-up
Complete single-use ADC technology from development through scale-up
 
How to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFFHow to reach High Plasma Protein Concentration with Single-Pass TFF
How to reach High Plasma Protein Concentration with Single-Pass TFF
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
 
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
High Productivity Membrane Chromatography: Enabling the Next Generation Biopr...
 

Similar to Webinar: Benefits of Monodisperse Activated PEGs in ADC Development

The Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCThe Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCMerck Life Sciences
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Merck Life Sciences
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...MilliporeSigma
 
Chempro Life Sciences Lab PPT.pptx
Chempro Life Sciences Lab PPT.pptxChempro Life Sciences Lab PPT.pptx
Chempro Life Sciences Lab PPT.pptxHiralZaveri2
 
cara Baca SWISSADME-TargetPred.pdf
cara Baca SWISSADME-TargetPred.pdfcara Baca SWISSADME-TargetPred.pdf
cara Baca SWISSADME-TargetPred.pdfVictorDelacroix2
 
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...Merck Life Sciences
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputMerck Life Sciences
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputMilliporeSigma
 
Analytical methods: key considerations to efficiently bring ADCs to the market
Analytical methods: key considerations to efficiently bring ADCs to the marketAnalytical methods: key considerations to efficiently bring ADCs to the market
Analytical methods: key considerations to efficiently bring ADCs to the marketQuality Assistance s.a.
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesMilliporeSigma
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesMerck Life Sciences
 
PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...
PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...
PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...QIAGEN
 
Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...Merck Life Sciences
 
Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...MilliporeSigma
 
Ko process-r-d-online-hi-jan2021b
Ko process-r-d-online-hi-jan2021bKo process-r-d-online-hi-jan2021b
Ko process-r-d-online-hi-jan2021bSteve Brough
 
Cad introduction 2019 30 min
Cad introduction 2019 30 minCad introduction 2019 30 min
Cad introduction 2019 30 minOskari Aro
 
Integrating Laboratory Services
Integrating Laboratory ServicesIntegrating Laboratory Services
Integrating Laboratory ServicesMedpace
 

Similar to Webinar: Benefits of Monodisperse Activated PEGs in ADC Development (20)

The Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCThe Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADC
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
Characterization of monoclonal antibodies and Antibody drug conjugates by Sur...
 
Chempro Life Sciences Lab PPT.pptx
Chempro Life Sciences Lab PPT.pptxChempro Life Sciences Lab PPT.pptx
Chempro Life Sciences Lab PPT.pptx
 
cara Baca SWISSADME-TargetPred.pdf
cara Baca SWISSADME-TargetPred.pdfcara Baca SWISSADME-TargetPred.pdf
cara Baca SWISSADME-TargetPred.pdf
 
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
Key to Successful Formulation Development for Lipid Based RNA Delivery and Va...
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita Rajput
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita Rajput
 
Analytical methods: key considerations to efficiently bring ADCs to the market
Analytical methods: key considerations to efficiently bring ADCs to the marketAnalytical methods: key considerations to efficiently bring ADCs to the market
Analytical methods: key considerations to efficiently bring ADCs to the market
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 
How to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC TherapiesHow to Accelerate and Enhance ADC Therapies
How to Accelerate and Enhance ADC Therapies
 
PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...
PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...
PCR - From Setup to Cleanup: A Beginner`s Guide with Useful Tips and Tricks -...
 
Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...
 
Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...Webinar: Effective and Efficient Design of a Downstream Purification Process ...
Webinar: Effective and Efficient Design of a Downstream Purification Process ...
 
Ko process-r-d-online-hi-jan2021b
Ko process-r-d-online-hi-jan2021bKo process-r-d-online-hi-jan2021b
Ko process-r-d-online-hi-jan2021b
 
Cad introduction 2019 30 min
Cad introduction 2019 30 minCad introduction 2019 30 min
Cad introduction 2019 30 min
 
Quality by Designs
Quality by DesignsQuality by Designs
Quality by Designs
 
SCoT and RAPD
SCoT and RAPDSCoT and RAPD
SCoT and RAPD
 
Final PPT
Final PPTFinal PPT
Final PPT
 
Integrating Laboratory Services
Integrating Laboratory ServicesIntegrating Laboratory Services
Integrating Laboratory Services
 

More from MilliporeSigma

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeMilliporeSigma
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...MilliporeSigma
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationMilliporeSigma
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...MilliporeSigma
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...MilliporeSigma
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...MilliporeSigma
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsMilliporeSigma
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...MilliporeSigma
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesMilliporeSigma
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...MilliporeSigma
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...MilliporeSigma
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?MilliporeSigma
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...MilliporeSigma
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...MilliporeSigma
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsMilliporeSigma
 
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...MilliporeSigma
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...MilliporeSigma
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...MilliporeSigma
 
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...MilliporeSigma
 
Introducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) Platform
Introducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) PlatformIntroducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) Platform
Introducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) PlatformMilliporeSigma
 

More from MilliporeSigma (20)

Launch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide AlternativeLaunch of our new Titanium Dioxide Alternative
Launch of our new Titanium Dioxide Alternative
 
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
The Viscosity Reduction Platform: Viscosity-reducing excipients for improveme...
 
Use of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein PurificationUse of Excipients in Downstream Processing to Improve Protein Purification
Use of Excipients in Downstream Processing to Improve Protein Purification
 
Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...Exploring the protein stabilizing capability of surfactants against agitation...
Exploring the protein stabilizing capability of surfactants against agitation...
 
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
The Viscosity Reduction Platform: Viscosity Reducing Excipients for Protein F...
 
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
The Role of BioPhorum Extractables Data in the Effective Adoption of Single-U...
 
The Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical AuditsThe Future of Pharma- and Biopharmaceutical Audits
The Future of Pharma- and Biopharmaceutical Audits
 
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
Moving your Gene Therapy from R&D to IND: How to navigate the Regulatory Land...
 
Identity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapiesIdentity testing by NGS as a means of risk mitigation for viral gene therapies
Identity testing by NGS as a means of risk mitigation for viral gene therapies
 
Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...Latest advancements of melt based 3D printing technologies for oral drug deli...
Latest advancements of melt based 3D printing technologies for oral drug deli...
 
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
CAR-T Manufacturing Innovations that Work - Automating Low Volume Processes a...
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?
 
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
Improve Operational Efficiency by Over 30% with Product, Process, & Systems A...
 
Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...Insights from a Global Collaboration Accelerating Vaccine Development with an...
Insights from a Global Collaboration Accelerating Vaccine Development with an...
 
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use SystemsRisk-Based Qualification of X-Ray Sterilization for Single-Use Systems
Risk-Based Qualification of X-Ray Sterilization for Single-Use Systems
 
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
Rapid Replication Competent Adenovirus (rRCA) Detection: Accelerate your Lot ...
 
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
The High Intensity Sweeteners Neotame and Sucralose: 2 Ways to ace the Patien...
 
The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...The Developability Classification System (DCS): Enabling an Optimized Approac...
The Developability Classification System (DCS): Enabling an Optimized Approac...
 
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...
EU GMP Annex 1 Draft - Closed System Design Consideration with Single-Use Sys...
 
Introducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) Platform
Introducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) PlatformIntroducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) Platform
Introducing our novel Sf9 rhabdovirus-negative (Sf-RVN®) Platform
 

Recently uploaded

pathology seminar presentation best ppt by .pptx
pathology seminar presentation best ppt by  .pptxpathology seminar presentation best ppt by  .pptx
pathology seminar presentation best ppt by .pptxAmanuelIbrahim
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxdrtabassum4
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...aunty1x2
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfsmartcare
 
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...GQ Research
 
Master the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingMaster the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingJoga Yoga Training
 
Enhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfEnhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfgajendrasinh1303
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
 
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)Chris Shade
 
What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...Rick Body
 
Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...
Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...
Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...aunty1x1
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxAnushriSrivastav
 
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxAnushriSrivastav
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisonersAhmed Elmi
 
Overcome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxOvercome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxrenewlifehypnosis
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health CareASKatoch1
 
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024Phinoj K Abraham
 
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxNose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxDr. Rabia Inam Gandapore
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...aunty1x1
 

Recently uploaded (20)

pathology seminar presentation best ppt by .pptx
pathology seminar presentation best ppt by  .pptxpathology seminar presentation best ppt by  .pptx
pathology seminar presentation best ppt by .pptx
 
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptxPT MANAGEMENT OF URINARY INCONTINENCE.pptx
PT MANAGEMENT OF URINARY INCONTINENCE.pptx
 
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...Contact Now  89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
 
Antibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptxAntibiotic Stewardship by Anushri Srivastava.pptx
Antibiotic Stewardship by Anushri Srivastava.pptx
 
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdfVirtual Health Platforms_ Revolutionizing Patient Care.pdf
Virtual Health Platforms_ Revolutionizing Patient Care.pdf
 
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
Healthcare Companion Robots: Key Features and Functionalities, Benefits, Chal...
 
Master the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga TrainingMaster the Art of Yoga with Joga Yoga Training
Master the Art of Yoga with Joga Yoga Training
 
Enhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdfEnhancing-Patient-Centric-Clinical-Trials.pdf
Enhancing-Patient-Centric-Clinical-Trials.pdf
 
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfCHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdf
 
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
Chris Shade BS MEd MS LPC-Associate "Presume" (What Do I Do?)
 
What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...What can we really do to give meaning and momentum to equality, diversity and...
What can we really do to give meaning and momentum to equality, diversity and...
 
Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...
Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...
Contact mE 👙👨‍❤️‍👨 (89O1183OO2) 💘ℂall Girls In MOHALI By MOHALI 💘ESCORTS GIRL...
 
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptxBOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
BOWEL ELIMINATION BY ANUSHRI SRIVASTAVA.pptx
 
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptxUrinary Elimination BY ANUSHRI SRIVASTAVA.pptx
Urinary Elimination BY ANUSHRI SRIVASTAVA.pptx
 
A Community health , health for prisoners
A Community health  , health for prisonersA Community health  , health for prisoners
A Community health , health for prisoners
 
Overcome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptxOvercome Your Phobias with Hypnotherapy.pptx
Overcome Your Phobias with Hypnotherapy.pptx
 
Integrated Mother and Neonate Childwood Illness Health Care
Integrated Mother and Neonate Childwood Illness  Health CareIntegrated Mother and Neonate Childwood Illness  Health Care
Integrated Mother and Neonate Childwood Illness Health Care
 
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024Occupational Therapy Management for Parkinson's Disease - Webinar 2024
Occupational Therapy Management for Parkinson's Disease - Webinar 2024
 
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptxNose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
Nose-Nasal Cavity & Paranasal Sinuses BY Dr.Rabia Inam Gandapore.pptx
 
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
Notify ME 89O1183OO2 #cALL# #gIRLS# In Chhattisgarh By Chhattisgarh #ℂall #gI...
 

Webinar: Benefits of Monodisperse Activated PEGs in ADC Development

  • 1. Merck KGaA Darmstadt, Germany Lisa L. McDermott Director, Process and Analytical Development Olaf Bartram Global Product Manager, PEGs and Innovative Technologies Benefits of monodisperse & Activated PEGs to Accelerate ADC Development
  • 2. The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
  • 3. Monodisperse PEGs in ADCs Presentation Overview 2 Executive Summary 3 1 4 Hydrophobicity Challenges Summary Critical PEG Attributes
  • 4. • Aggregation of Final ADC • Drug Load Limitations • High loaded species need to be removed • Limit R&D to low DAR Analogues • PK/PD impact • Fast clearance rate • Rate increased with increasing DAR • increased lipophilicity • Decreased therapeutic window Monodisperse PEGs in ADCs Challenges Encountered with Hydrophobic Toxins Impact of toxin solubility
  • 5. • Alternative scaffolds • Optimize linker to offset lipophilicity of payload • Site specific payload attachment • Payload bearing site modification • SAR mAb, payload, linker and conjugation method • Alternative Formulation or Additives Monodisperse PEGs in ADCs Challenges Encountered with Hydrophobic Toxins Tools
  • 6. Monodisperse PEGs in ADCs Impact of Drug Loading on Efficacy Higher DARs - Accelerates ADC clearance Higher DARs - Non-linear impact on tumor growth Kevin J. Hamblett et al. Clin Cancer Res 2004;10:7063-7070 Pharmacokinetics of cAC10 and cAC10– antibody-drug conjugates. SCID mice were injected via the tail vein with 10 mg/kg cAC10, E2, E4, and E8. Plasma samples were analyzed by ELISA to determine the antibody or antibody-drug conjugate concentration. DAR2 DAR8 DAR4 DAR0
  • 7. Why PEGs can help? • Improved pharmacokinetics • Enhanced solubility • Improved stability • Increased circulation time • Decreased amount of protein required for therapeutic efficacy • Decreased dosing frequency due to optimized biodistribution • Reduced renal clearance increases circulation time • Decreased toxicity • Improved safety profile • Reduced immunogenicity • Reduced antigenicity • Reduced proteolysis • Generally recognized as safe (GRAS status by FDA) Dumb-Bell like PEG-drug structure Monodisperse PEGs in ADCs
  • 8. Monodisperse PEGs in ADCs Transfer of the protein pegylation concept to ADCs with DAR8: what is the desired PEG size? Maleimide-PEG-Glucuronide-MMAE with variable PEG lengths Burke et al., Mol Cancer Ther 16(1) 116
  • 9. Monodisperse PEGs in ADCs Pharmacokinetic and clearance is a function of PEG length, demonstrated for a DAR8 ADC Burke et al., Mol Cancer Ther 16(1) 116
  • 10. Monodisperse PEGs in ADCs Increasing PEG length shows a positive effect on Pharmacodynamic and increased tolerability and mouse survival rate Burke et al., Mol Cancer Ther 16(1) 116
  • 11. Monodisperse PEGs in ADCs Selected Microtubule Targeting Drug Linkers that contain PEG Groups DBCO-PEG4-linker MMAF payload (http://www.globalengage.co.uk/biologics/docs/Steiner.pdf , Sutro) PEG4, Mar. Drugs 2017, 15, 99 https://pdfs.semanticscholar.org/40fe/c075fbef09881fd87402276267645af078a7.pdf Mol Cancer Ther; 16(1) January 2017, 116-123 SGN-CD48a, PEG12, SeattleGenetics
  • 12. Monodisperse PEGs in ADCs Selected DNA Targeting Drug Linkers that Contain PEG Groups Nature Reviews, 2017 (16) 315 PEG3, Immunogen ACS Med Chem Lett 2016, 7, 983 PEG8, Spirogen Mol Cancer Ther 2018, 17(10), 2176 , Immunogen Oncotarget Vol.6, No.26, 22496 PEG8, Immunomedics
  • 13. Monodisperse PEGs in ADCs Linear and branched PEG in ADC examples CD-70, PEG2+2*4 , Ambrex US20150141624A1 HU2H11, PEG5, Sanofi Molecules 2017, 22(8), 1281
  • 14. Monodisperse PEGs in ADCs Presentation Overview 2 Executive Summary 3 1 4 Hydrophobicity Challenges Summary Critical PEG Attributes
  • 15. 1. PEGs are well known substances, generally recognized as safe (GRAS), biologically inert with hydrophilic properties 2. Widely used as non-toxic auxiliary materials in multiple technical applications and amongst others in cosmetics and food and pharmaceuticals (such as medical treatment of constipation) 3. After synthetic activation PEGs can be conjugated (PEGylated) with proteins, peptides, small molecules or can act as linkers in ADCs. 4. PEGylated products show improved pharmacokinetics, increased circulation time and decreased toxicity. Introduction Polyethylene Glycol (PEG) Monodisperse PEGs in ADCs
  • 16. 16 Monodisperse PEGs in ADCs Polydisperse PEGs • Statistical distribution results from equal probabilities of ethylene oxide polymerizations. There is only a neglectable difference between PEG fractions of different chain lengths. • Thus even under the most ideal conditions a distribution will be obtained. If the conditions are not ideal, the distribution will deteriorate even more. Polymerizations will result always in a molecular weight distribution.
  • 17. 17 Monodisperse PEGs in ADCs Monodisperse PEGs • Monodisperse PEGs do have an impact on the pharmacokinetic and pharmacodynamics of your ADC • Production of monodisperse PEGs by purification of polydisperse PEGs or synthesis of defined PEG units with the same molecular weight • Typically used for ADCs are PEG4 – PEG24 units • Maleimide as functional group is targeting cysteine at the antibody • Functional azide group connects to payload • High purity and defined impurity profile are beneficial for registration • High GMP level required for successful commercialisation of your ADC ADCs require monodisperse PEGs as linkers with a uniform molecular mass.
  • 18. 18 Monodisperse PEGs in ADCs Monodisperse PEGs • Target purity of 90-95% or higher - depends on analytical method • Sensitive to oxidation and hydrolysis - determined via derivatization • Adsorption of elemental impurities (heavy metals), salts, polar compounds  Control elemental impurities via ICP-MS  Control residual solvents and reagents via GC, IC, KF and HPLC Purity of monodisperse PEGs is the main quality parameter.
  • 19. Separation of single PEG units in relation to PEG size Figure: Separation of different PEGs using HPLC-CAD. Sample concentration for all: 0.1 mg/mL. Source: C. Theiss, U. Holzgrabe / Journal of Pharmaceutical and Biomedical Analysis 160 (2018) 212–221 Monodisperse PEGs in ADCs Lower number of PEG units are easier to separate. Approx. 7-23 PEG units
  • 20. Comparison of detector responses CAD ELSD UV Mass on detector Relativedetectorresponse  Both ELSD and CAD have non-linear response curves compared to UV.  ELSD tends to underestimate low level signals.  LoQ is typically lower for CAD compared to ELSD.  CAD overestimates small impurities.  For both - CAD and ELSD - small, semi- volatile compounds might be evaporated and therefore not visible or underestimated.  Understanding the characteristics of the different detectors is key for the correct interpretation of analytical results. CAD = Charged Aerosol Detector ELSD = Evaporative Light Scattering Detector UV = UV Detector Monodisperse PEGs in ADCs CAD-ELSD-UV Widely used UV detectors are not applicable for PEGs as such.
  • 21. ELSD  Purity: 98.9 % area  Largest impurity: 1.0 % area  Number of impurities: 5 Monodisperse PEGs in ADCs Case study: Same sample measured with Evaporative Light Scattering Detector (ELSD) and Charged Aerosol Detector (CAD)
  • 22. ELSD  Purity: 98.9 % area  Largest impurity: 1.0 % area  Number of impurities: 5 Monodisperse PEGs in ADCs Case study: Same sample measured with Evaporative Light Scattering Detector (ELSD) and Charged Aerosol Detector (CAD) CAD  Purity: 89.0 % area  Largest impurity: 5.8 % area  Number of impurities: 18 Interpretation of CAD and ELSD derived results need solid analytical knowledge
  • 23. Penta ethylene glycol (PEG 5) Hexa ethylene glycol (PEG 6) Monodisperse PEGs in ADCs Gas Chromatography (GC) for volatile compounds PEGs up to approx. six ethylene glycol units are volatile enough to be analyzed by GC.
  • 24. Monodisperse PEGs in ADCs Presentation Overview 2 Executive Summary 3 1 4 Hydrophobicity Challenges Summary Critical PEG Attributes
  • 25. • Low solubility of lipophilic payloads limits high DAR ADCs • PEGs in ADC linker enables higher soluble ADCs with higher DARs • Quality, especially purity of PEGs in ADC is a key parameter for regulatory success • Determination of PEG purity depends significantly on analytical setup Monodisperse PEGs in ADCs Summary Overcoming ADC Solubility Issues
  • 26. Merck and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. © 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Editor's Notes

  1. Non-denaturing water-soluble = chem properties for biological app, Non toxic, non-immunogenic How do they impact potency selectivity and PKPD
  2. Non-denaturing water-soluble = chem properties for biological app, Non toxic, non-immunogenic How do they impact potency selectivity and PKPD
  3. Thank you, Lisa and welcome from my side!
  4. Before we will talk about critical attribute of Polyethylene Glycol and the analytical challenges connected with that, I would like to give a short introduction. PEGs are used in many applications and industrial field, e.g. as humectant in food, dispersant in cosmetic, or even as ingredient of ink for inkjet printers. They are very water-soluble and generally recognized as safe (GRAS). The fact that they are also biologically inert make PEGs applicable for medical treatment. A well known application is the treatment of constipation. Via the addition of functional groups either on one or both ends of the polymer, PEGs can be conjugated to proteins, peptides or small molecules. Those –s so called- PEGylated products show improved pharmacokinetics, increased circulation time, decreased toxicity. Today we are focusing on PEGs as linker between an antibody and a payload molecule.
  5. The classical synthetic of PEGs shown here at the left side, is a polymerization of ethylene oxide that connects randomly and with an equal probability to the build polyethylene chains. The result is a statistical distribution of the molecular weight of this polydisperse PEG, shown in the MALDI-TOFF chromatogram on the right side. Each signal reflects the amount of PEG units of a polydisperse PEG. The level of distribution depends on the process conditions during polymerization. Needless to say that using such a PEG with multiple MW fractions as linker for ADCs would be not beneficial.
  6. With the use of so called monodisperse PEGs this issue can be solved. Since PEGs as linkers do impact significantly the pharmacokinetics and pharmacodynamics of ADCs, highly defined and pure PEGs are necessary. Monodisperse PEGs are produced either via purification of polydisperse PEGs or the synthesis of uniform PEG units leading to a defined molecular weight. Typical chain lengths used as linkers are 4 to 24 units of PEGs but also larger monodisperse PEGs can be manufactured. The right graph shows a PEG52 analyzed with MALDI-TOF with a clear separation of each PEG unit. A typical functional group is Maleimide to conjugate with the thiol containing amino acids of the anti body. At the other end of the PEG, an Azide group is used to connect to the payload via click chemistry. Beside the impact on pharmacokinetics and pharmacodynamics, the uniform molecular weight of the PEG makes it much easier to be analytically characterized. This can be beneficial the registration of the ADC during all clinical phases. Last but not least supply monodisperse PEG meeting c-GMP requirements, is crucial when it comes to commercialization.
  7. The target purity of monodisperse PEGs is usually in the range of 90-95%, but depends very much on the chosen analytical setup. I will show an example for that. Regarding sensitivity of oxidation and hydrolysis monodisperse PEGs don’t differ from polydisperse. To control this a chemical derivatization is needed in front of every analytical run. PEGs can easily adsorb elemental impurities, salt or polar compounds, which is analyzed by state of the art methods for ICP-MS, GC, IC, Karl-Fisher and HPLC.
  8. When it comes to PEG analytics we are facing some challenges. The separation of PEG units depends on the molecular weight, illustrated here by a graph from Theiss and Holzgrabe. The ADC relevant range of PEG 300-1000 Dalton shows already a significant difference in peak separation which has an impact on differentiation between purity and impurities. This has to be taken into account especially during the evaluation of your optimal PEG length and the respective analytical development.
  9. In addition the use of different detectors of HPLC systems for the determination of purity needs to be taken into consideration. With the absence of double bindings the most preferred UV light detector can not be used for monodisperse PEGs. Applicable detectors are ELSD and CAD, but both need a solid analytical expertise for the correct interpretation of results. ELSD is underestimating low level signals, on the other hand CAD overestimates them. Both detectors evaporates volatile compounds which are therefore not visible.
  10. Looking at an example of an monodisperse PEG measured with a HPLC-ELSD delivers a purity of almost 99%, 5 impurities, the largest with 1 aerea %.
  11. The same sample measured with a CAD leads to a drop in purity to 89% an increased number and content of impurities. This shows how diverse results can be using different analytical methods. Since there is no clear scenario whether using the one or the other technology, it is more about using both and to have the right partner with a broad expertise in analytical development to draw the right conclusion out of the results.
  12. On my last slide I would like to show that Gas chromatography is an option for small PEG units. Up to PEG6 units are volatile enough. Shown her is a PEG5 and PEG6 unit. Last one also multiple impurities have been detected. Now its time for two poll questions. How do you determine the purity of your monodisperse PEG? -read- And What do you or what would you request most from your PEG supplier? -read- Thank you your input is very valuable for us.
  13. Finally I would like to summarise Lisa explained that the low solubility of the lipophilic payloads is one of the main issues for ADCs PEGs used as linkers can help to overcome this to achieve higher DARs Especially the purity of monodisperse PEGs will determine the successful development & registration of your ADC The analytic of monodisperse PEGs is impacted by the used or available setup. ELSD CAD can be used but results need interpretation. GC is an option of smaller PEG units up to 6.